Sign In
Buy TGTX
$40.11
+3.47 (+9.47%)
At Close: Jun 03, 2026
Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis
07:01am, Monday, 02'nd Mar 2026
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therap
TG Therapeutics Q4 Earnings Call Highlights
05:05am, Monday, 02'nd Mar 2026
TG Therapeutics (NASDAQ: TGTX) executives highlighted rapid revenue growth for BRIUMVI in 2025, expanding adoption in relapsing multiple sclerosis (RMS), and multiple upcoming clinical and regulatory
TG Therapeutics: 'Strong Buy' On BRIUMVI's Massive Growth And Possible Expansion
02:31pm, Friday, 27'th Feb 2026
TG Therapeutics remains a "Strong Buy," driven by robust BRIUMVI revenue growth and ambitious expansion initiatives. The company reported $594 million in 2025 U.S. BRIUMVI sales, a 90% YoY increase, a
TGTX Q4 Earnings Lag Estimates, Briumvi Sales Drive Top Line
01:10pm, Friday, 27'th Feb 2026
TG Therapeutics misses Q4 earnings estimates, but total revenues surge 78% y/y on strong Briumvi sales. The company reaffirms its 2026 revenue outlook.
TG Therapeutics, Inc. (TGTX) Q4 2025 Earnings Call Transcript
12:27pm, Thursday, 26'th Feb 2026
TG Therapeutics, Inc. (TGTX) Q4 2025 Earnings Call Transcript
TG Therapeutics (TGTX) Misses Q4 Earnings Estimates
10:56am, Thursday, 26'th Feb 2026
TG Therapeutics (TGTX) came out with quarterly earnings of $0.14 per share, missing the Zacks Consensus Estimate of $0.35 per share. This compares to earnings of $0.15 per share a year ago.
TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance
07:00am, Thursday, 26'th Feb 2026
Fourth quarter and full year 2025 total revenue of $192.6 million and $616.3 million, including BRIUMVI U.S. net revenue of $182.7 million and $594.1 million, respectively
TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q4 Release
11:01am, Monday, 23'rd Feb 2026
TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update
07:30am, Monday, 23'rd Feb 2026
Conference Call to be Held Thursday, February 26, 2026, at 8:30 am ET Conference Call to be Held Thursday, February 26, 2026, at 8:30 am ET
TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Rating of “Moderate Buy” from Brokerages
03:26am, Saturday, 14'th Feb 2026
TG Therapeutics, Inc. (NASDAQ: TGTX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the six brokerages that are presently covering the company, Marketbeat reports. Tw
TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis
04:17pm, Sunday, 08'th Feb 2026
Campaign debuted during Super Bowl LX and introduced www.NextInMS.com, a new platform designed to create space for honest conversation among people living with MS Campaign debuted during Super Bowl LX
NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy), to be presented at the Americas C
Hussman Strategic Advisors Sells 126,000 TG Therapeutics Shares
05:55pm, Monday, 02'nd Feb 2026
Hussman Stratgic Advisors sold 126,000 shares of TG Therapeutics. The fund no longer holds any shares.
John Hussman's Strategic Moves: Qualcomm Inc. Takes Center Stage with 1.13% Portfolio Impact
01:01pm, Monday, 02'nd Feb 2026
Exploring the Investment Strategies of John Hussman (Trades, Portfolio) in Q4 2025 John Hussman (Trades, Portfolio) recently submitted the 13F filing for the f
TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Rating of “Moderate Buy” from Brokerages
06:13am, Tuesday, 20'th Jan 2026
Shares of TG Therapeutics, Inc. (NASDAQ: TGTX - Get Free Report) have received a consensus rating of "Moderate Buy" from the six brokerages that are currently covering the company, MarketBeat reports.
